Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer (2023)

Peer-Reviewed Study · Chang CS, Ryu JY, Choi JK, Cho YJ, Choi JJ, Hwang JR, Choi JY, Noh JJ, Lee CM, Won JE, Han HD, Lee JW · April 24, 2023

Chang CS et al., 2023-04-24: Fenbendazole reduced proliferation of chemosensitive and chemoresistant ovarian cancer cells in culture, but oral fenbendazole did not reduce tumour growth in mouse xenografts; only a PLGA nanoparticle formulation showed in vivo activity.

However, in cell line xenograft mouse models, there was no effect of oral FZ treatment on tumor reduction.

Chang CS et al., 2023-04-24: Fenbendazole reduced proliferation of chemosensitive and chemoresistant ovarian cancer cells in culture, but oral fenbendazole did not reduce tumour growth in mouse xenografts; only a PLGA nanoparticle formulation showed in vivo activity. C2 Chang 2023. Study type: in vitro ovarian cancer lines plus cell-line xenograft and patient-derived xenograft mice; N not stated in abstract; country South Korea (Samsung Medical Center, Sungkyunkwan University); oral and intraperitoneal dosing, doses in full text (PMC10482585); funder Korea Medical Device Development Fund KMDF_PR_20200901_0153-2022 and NRF 2020R1C1C1007482; conflicts: 'No potential conflict of interest relevant to this article was reported'; maker: not stated (PLGA nanoparticles prepared by the authors); comparators: vehicle, oral vs intraperitoneal, free drug vs nanoparticle. Limit: free oral fenbendazole did not shrink xenografts. Citation: J Gynecol Oncol 34(5), Sep 2023. Also filed as FBC-35 (claims C2, C7). Study type: animal.